BioMed Ventures
VC Fund
San Diego, United States
BioMed Ventures is an investment company based in the United States.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries BioMed Ventures invests in
BiotechnologyMedicalHealth CareBiopharmaTherapeutics
Stages BioMed Ventures invests in
Series ASeries BSeedSeries CSeries D
Countries BioMed Ventures invests in
United States
Investment Focus
Industry
- Biotechnology 7 (88%)
- Medical 5 (63%)
- Health Care 4 (50%)
- Biopharma 2 (25%)
- Therapeutics 2 (25%)
Stage
- Series A 2 (25%)
- Series B 2 (25%)
- Seed 1 (13%)
- Series C 1 (13%)
- Series D 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Fauna Bio
|
Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bioleverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases. | $9M / Seed / Sep 21, 2021 | |
Effector Therapeutics
|
eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4Fcomplex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select messenger RNA into proteins that are frequent culprits in key disease driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK 1/2 inhibitor. KICKSTART, a randomized, double-blind, placebo controlled Phase 2b trial of tomivorsertib in NSCLC in combination with pembrolizumab is currently open for enrollment. Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently in the dose-escalation portion of a Phase 1/2 trial, with Phase 2a expansion cohorts expected to initiate in the second half of 2021. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. | $60M / Post-IPO Equity / Aug 26, 2021 | |
Amplyx Pharmaceuticals
|
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating andlife-threatening diseases that affect people with compromised immune systems.Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California. | $53M / Series C / May 19, 2020 | |
Compass Therapeutics
|
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeuticsthat can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. | $49M / Series A / Jul 12, 2018 | |
NeuroVia
|
NeuroVia, Inc. is committed to addressing unmet medical needs in neurological diseases with the primary goal to arrest the onset of devastating neurological deficits associated with X-ALD. | $14M / Series A / Jul 20, 2017 | |
Sensely
|
Sensely is a developer of avatar and chatbot-based platform designed to assist insurance plan members and patients. The company's platform leverages conversational interfaces and provides virtual assistant solutions to insurance companies, pharmaceutical clients, and hospital systems worldwide, enabling enterprises to converse with theirmembers in an entirely new way, combining the empathy of human conversation with the efficiency and scalability of the technology. | $8M / Series B / Feb 14, 2017 | |
TRACON Pharmaceuticals
|
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 smallmolecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development, shares in the cost and risk of clinical development, and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States. | $27M / Series B / Sep 22, 2014 | |
NanoString Technologies
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.NanoString's products are based on a novel digital molecularbarcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. | $20M / Series D / Nov 07, 2011 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does BioMed Ventures invest in?
BioMed Ventures invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did BioMed Ventures last invest?
The most recent investment recorded for BioMed Ventures closed in Sep 2021. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
